IP Verse

Calcifediol Soft Capsules - EP3204047

The patent EP3204047 was granted to Faes Farma on May 27, 2020. The application was originally filed on Feb 5, 2016 under application number EP16702960A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3204047

FAES FARMA
Application Number
EP16702960A
Filing Date
Feb 5, 2016
Status
Granted And Under Opposition
Apr 24, 2020
Publication Date
May 27, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DSM NUTRITIONAL PRODUCTSMar 1, 2021KRAUS & LEDERER PARTGMBBADMISSIBLE
PATENTANWALTSFeb 26, 2021FABRYADMISSIBLE
HELBIGFeb 18, 2021MEISSNER BOLTE PARTNERSCHAFT MBBADMISSIBLE

Patent Citations (34) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
EXAMINATIONWO2008134512
INTERNATIONAL-SEARCH-REPORTEP1208843
INTERNATIONAL-SEARCH-REPORTWO2007092755
INTERNATIONAL-SEARCH-REPORTWO2008097646
OPPOSITIONCA2570649
OPPOSITIONEP0301167
OPPOSITIONEP0629405
OPPOSITIONEP1208843
OPPOSITIONJPH054925
OPPOSITIONUS2002081331
OPPOSITIONUS2003191093
OPPOSITIONUS2005008581
OPPOSITIONUS2005065124
OPPOSITIONUS2005142185
OPPOSITIONUS2005175686
OPPOSITIONUS2006009425
OPPOSITIONUS2007259035
OPPOSITIONUS2010255085
OPPOSITIONUS2011052682
OPPOSITIONUS2011105444
OPPOSITIONUS4532126
OPPOSITIONUS6251426
OPPOSITIONWO03070156
OPPOSITIONWO03086415
OPPOSITIONWO2007038428
OPPOSITIONWO2007092755
OPPOSITIONWO2008097646
OPPOSITIONWO2008134512
OPPOSITIONWO2009047644
OPPOSITIONWO2010011906
OPPOSITIONWO2012047098
OPPOSITIONWO2014040921
OPPOSITIONWO2014143941
OPPOSITIONWO8403416

Non-Patent Literature (NPL) Citations (41) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- anonymous, "Neobee MEDIUM CHAIN TRIGLYCERIDES", Stepan - Brochure, (20120300), URL: https://www.stepan.com/content/dam/stepan-dot-com/webdam/website-product-documents/literature/food-nutrition-pharmaceutical/NEOBEEBrochure.pdf, XP055782368
OPPOSITION- BERGSTROM et al., BERGSTROM et al., James Swarbrick, Encyclopedia of Pharmaceutical Technology. 3rd ed., Informa Healthcare, (20070000), vol. 1, pages 419 - 430, XP055781709
OPPOSITION- BERGSTROM et al., "Capsules, soft", Encyclopedia of Pharmaceutical Technology, (20070000), vol. 1, no. Third Edition, pages 419 - 430, XP055781709
OPPOSITION- BISCHOFF-FERRARI H.A., "Chapter relative effects of vitamin D3 and calcifediol", Nutritional Influences on Bone Health, London, (20130000), pages 189 - 196, XP055790776
OPPOSITION- "Calderol", Marjorie A Duffy, Physicians' Desk Reference, Medical Economics Data, (19920000), page 1635, XP055782342
OPPOSITION- "CALDEROL", Physician's Desk Reference, (19920000), vol. 420, pages 1635 - 1636, XP055782342
OPPOSITION- "Capsules, Soft", James Swarbrick, Clinical Pharmacology and Biopharmaceutics. 3rd ed., Informa Healthcare, (2007), pages 419 - 430, XP055781709
OPPOSITION- G. A. LEICHTMANN et al., "Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease and intestinal resection", Am J Clin Nutr, (19910901), vol. 54, pages 548 - 552, XP055789901
OPPOSITION- HADDAD et al., "Acute administration of 25-hydroxycholecalciferol in man", J. Clin. Endocrinol. Metab., (19760000), vol. 42, pages 284 - 290, XP002438498
OPPOSITION- "Hidroferol 0,1 mg/ml gotas orales en solución", Technical Datasheet, (20130300), XP055790743
OPPOSITION- "Hidroferol Gotas", MEDICOM, (19970000), page 405, XP055790746
OPPOSITION- "Hidroferol", Vademecum Internacional - Especialidades farmaceuticas y biológicas - Productos y artículos de parafarmacia. Métodos de diagnóstico, MEDICOM, (20040000), page 697, XP055781696
OPPOSITION- H. NECHAMA et al., "THE INTESTINAL ABSORPTION OF VITAMIN D AND ITS METABOBOLITES", Journal of Molecular Medicine, (19770000), vol. 2, pages 413 - 422, XP055789900
OPPOSITION- HUTCHISON et al., "Soft gelatin capsules", Pharmaceutics. The Science of Dosage Form Design, (20010000), pages 461 - 472, XP055790713
OPPOSITION- JAMES SWARBRICK et al., "Capsules, Soft", Encyclopedia of Pharmaceutical Technology, (20070000), vol. 1, pages 419 - 430, XP055781709
OPPOSITION- J. G. HADDAD et al., "Acute Administration of 25-Hydroxycholecalciferol in Man", The Journal of Clinical Endocrinology & Metabolism, (19760613), vol. 42, no. 2, pages 284 - 290, XP055780382
OPPOSITION- "Kapitel 11. Kapseln", R. VOIGT, Pharmazeutische Technologie, Deutscher Apoteker Verlag, (20100000), XP055781715
OPPOSITION- "Kapitel 1.8 Weichkapseln", Cornelia M Keck; Rainer H Müller; Sven Stegemann, Moderne Pharmazeutische Technologie, (20090000), pages 43 - 47, XP055789896
OPPOSITION- NIEVES J.W., "Skeletal effects of nutrients and nutraceuticals, beyond calcium and vitamin D", Osteoporos. Int., (20130000), vol. 24, pages 771 - 786, XP055790760
OPPOSITION- "Packaging and Labering", Shayne Cox Gad, Pharmaceutical Manufacturing Handbook - Production and Processes, Wiley - Interscience, (20080000), page 164, XP055781704
OPPOSITION- R. RECKER et al., "The Efficacy of Calcifediol in Renal Osteodystrophy", Arch Intern Med, (19780515), vol. 138, pages 857 - 863, XP055687464
OPPOSITION- "Soft elastic capsules", Alfonso R. Gennaro, Remington: The Science and Practice of Pharmacy. 21st ed., Lippincott Williams, (20060000), page 923, XP055781718
OPPOSITION- STRICKLEY et al., "Solubilizing Vehicles for Oral Formulation Development", Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutic s, (20070000), XP055790725
OPPOSITION- SUNYECZ JA, "The use of calcium and vitamin D in the management of osteoporosis", Ther. Clin. Risk Manag., (20080000), vol. 4, no. 4, pages 827 - 836, XP055790753
OPPOSITION- VITERI F.E., "Iron supplementation for the control or iron deficiency in polulations at risk", Nutr. Rev., (19970000), vol. 55, no. 6, pages 195 - 209, XP055790768
OPPOSITION- Rampurna Prasad Gullapalli, "Soft Gelatin Capsules (Softgels)", Journal of Pharmaceutical Sciences, (20101018), vol. 99, no. 10, pages 4107 - 4148, XP055090285
OPPOSITION- R. P. GULLAPALLI, "Soft Gelatin Capsules (Softgels)", Journal of Pharmaceutical Sciences, (20101018), vol. 99, no. 10, pages 4107 - 4148, XP055090285
OPPOSITION- CARMEL et al., "The 25(OH)D level needed to maintain a favorable bisphosphonate response is ?33 ng/ml", Osteoporos Int., (20120000), vol. 23, no. 10, doi:10.1007/s00198-011-1868-7, pages 2479 - 2487, XP035112974
OPPOSITION- N. GURSOY et al., "Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs", Biomedicine & Pharmacotherapy, (20040000), vol. 58, doi:10.1016/j.biopha.2004.02.001, pages 173 - 182, XP002500493
OPPOSITION- A. JETTER et al., "Pharmacokinetics of oral vitamin D3 and calcifediol", Bone, (20140201), vol. 59, pages 14 - 19, XP055377077
OPPOSITION- A. GONCALVES et al., "Fat-soluble vitamin intestinal absorption: Absorption sites in the intestine and interactions for absorption", Food Chemistry, (20140916), vol. 172, pages 155 - 160, XP029094049
OPPOSITION- GONCALVES et al., "Fat-soluble vitamin intestinal absorption: Absorption sites in the intestine and interactions for absorption", Food Chem., (20150000), vol. 172, doi:10.1016/j.foodchem.2014.09.021, pages 155 - 160, XP029094049
OPPOSITION- M. PETKOVICH et al., "Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation", Journal of Steroid Biochemistry & Molecular Biology, (20141122), vol. 148, no. 148, pages 283 - 289, XP029145182
OPPOSITION- T. C. B. STAMP, "Intestinal Absorption of 25-Hydroxycholecalciferol", The Lancet, (19740720), vol. 304, no. 7873, pages 121 - 123, XP055780355
OPPOSITION- CURTIS et al., "Differences in bioavailability between oral cyclosporine formulations in maintenance renal transplant patients", Am. J. Kidney Dis., (19990000), vol. 34, doi:10.1016/S0272-6386(99)70044-2, pages 869 - 874, XP027421562
OPPOSITION- P. BOREL et al., "Vitamin D Bioavailability: State of the Art", Crit Rev Food Sci Nutr, (20150729), vol. 55, no. 9, pages 1193 - 1205, XP055789912
OPPOSITION- J. E. COMPSTON et al., "Plasma levels and intestinal absorption of 25-hydroxyvitamin D in patients with small bowel resection", Gut, (19770301), vol. 18, pages 171 - 175, XP055789910
OPPOSITION- M. D. SITRIN et al., "Comparison of vitamin D and 25-hydroxyvitamin D absorption in the rat", American Journal of Physiology, (19820401), vol. 242, no. 4, pages G326 - G332, XP055780357
OPPOSITION- M. D. SITRIN et al., "Comparison of vitamin D and 25-hydroxyvitamin D absorption in the rat", Am J Physiol, (19820401), vol. 242, no. 4, pages G326 - 332, XP055780357
OPPOSITION- R. MENTAVERRI, "Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule", Nutrients, (20190326), vol. 11, no. 3, page 703, XP055781699
OPPOSITION- K. D. CASHMAN et al., "Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults", American Journal of Clinical Nutrition, (20120502), vol. 95, no. 6, pages 1350 - 1356, XP055620614

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents